Conversely, a Phase 1 trial investigating the combination treatment of GV1001 with GM-CSF and gemcitabine in 28 patients with unresectable pancreatic cancer demonstrated a satisfactory safety profile, yet the induced immune response was weak and short-lived [61]. This evidence concerns the gene CSF2 and familial pancreatic carcinoma.